More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$180.22B
EPS
3.62
P/E ratio
10.8
Price to sales
3.57
Dividend yield
2.843%
Beta
0.694454
Previous close
$41.60
Today's open
$40.72
Day's range
$40.23 - $40.96
52 week range
$35.12 - $64.16
show more
CEO
Maziar Mike Doustdar
Employees
66700
Headquarters
Bagsvaerd,
Exchange
New York Stock Exchange
Shares outstanding
4.43B
Issue type
American Depository Receipt
Healthcare
Biotechnology & Life Sciences
Weight-loss drugs' hit to UK grocery spending tops £1 billion, Worldpanel says
The impact of weight-loss drugs on UK grocery spending has surpassed £1 billion ($1.32 billion), as new pill formats and rising uptake among men accelerate their use, researcher Worldpanel by Numerator said on Thursday.
Reuters • 7 hours ago

Novo Nordisk: The Worst May Be Behind
Novo Nordisk A/S remains a long-term Buy: its wide moat and falling capital expenditure support higher free cash flow. NVO raised 2026 free cash flow guidance to DKK 60–70 billion while guiding for adjusted sales and operating profit between a 2% decline and 2% growth. NVO's Wegovy pill and pipeline diversification support growth, although competition, pricing pressure, and semaglutide's 2032 patent expiration threaten sales.
Seeking Alpha • 15 hours ago

Johnson & Johnson vs. Novo Nordisk: Steady Uptrend vs.
Johnson & Johnson currently exhibits a stronger overall position by generating a substantially larger total revenue volume than Novo Nordisk. Johnson & Johnson maintained a consistent quarter-over-quarter upward trajectory, while Novo Nordisk reported mostly flat U.S. dollar figures with the exception of one isolated spike.
The Motley Fool • Nov 17, 2026

Eli Lilly vs. Novo Nordisk: Which GLP-1 Stock Is a Better Buy for 2027?
Eli Lilly has achieved explosive revenue growth fueled by its expanding portfolio of next-generation metabolic and weight-loss drugs. Novo Nordisk maintains a deep global reach with established diabetes and obesity treatments currently available in more than 50 countries.
The Motley Fool • Nov 17, 2026

Novo Nordisk: The Thesis Is Working, The Stock Just Hasn't Noticed Yet
I retain a Strong Buy on Novo Nordisk: improving cash flow and cost discipline reinforce an inexpensive valuation at 10.89 times non-GAAP earnings. NVO raised free cash flow guidance to DKK 60–70 billion after generating DKK 28.4 billion in Q3; gross margin rose to 82.1%. NVO's obesity pill is scaling internationally, while CagriSema's lower-dose data and expected FDA decision support a credible path toward an early 2027 launch.
Seeking Alpha • Nov 17, 2026

Novo Nordisk Shares Rise on Positive Weight-Loss Data, Hemophilia Drug Approval
The Danish drugmaker released encouraging results from studies and European regulators approved a hemophilia treatment, pushing the stock higher premarket.
WSJ • Nov 16, 2026

Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo released full results from a late-stage trial showing Wegovy helped children ages 6 to under 12 with obesity significantly lower their body mass index. Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.
CNBC • Nov 16, 2026

NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema
Novo secures EC approval for Frehemgo while CagriSema delivers up to 21% weight loss, adding momentum to its turnaround efforts amid intensifying obesity drug competition.
Zacks Investment Research • Nov 16, 2026

New research shows weight-loss drugs could be an effective option for children as young as 6 years old
Novo Nordisk's study of GLP-1s in children as young as 6 years old worked for shedding pounds but raised questions about growth rates.
WSJ • Nov 16, 2026

Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027
Eli Lilly is surging, with revenue up 39% in the third quarter and a retatrutide filing planned for early 2027. Novo is bouncing back on oral Wegovy, with a CagriSema decision due soon.
The Motley Fool • Nov 15, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Novo Nordisk A/S commission-free¹. Build wealth for the long term using automated trading and transfers.